Skip to main content

Prurigo Nodularis News

FDA Approves Nemluvio for Prurigo Nodularis

THURSDAY, Aug. 15, 2024 – The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for adult patients living with prurigo nodularis. Nemluvio, administered as a prefilled pen for...

FDA Approves Nemluvio (nemolizumab) for the Treatment of Adult Patients with Prurigo Nodularis

Zug, Switzerland – August 13, 2024 – Galderma today announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for th...

Dupixent (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials About 75,000 adults in the U.S. living with prurigo nodularis...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Dermatological Disorders

Related drug support groups

Dupixent, dupilumab